Amplia Therapeutics Limited (ASX:ATX) Annual Report 2021



The latest annual report of Amplia Therapeutics Limited (ATX) was published on 31 Mar 2021. An annual report is a document that public corporations must provide annually to shareholders that describes their operations and financial conditions. Typically, an annual report will contain sections such as General corporate information, Operating and Financial highlights, Letter to shareholders from the CEO, Financial statements etc.

Key Statistics - ATX Annual Results

Amounts in AUD

Total Revenue
1.53M
Gross Profit
1.22M
EBIT
-2.34M
Net Tangible Assets
2.4M
Net Income
-2.28M
Capital Expenditures
-5.35k

ATX Income Statement 2021 Annual Report

As per the latest Income Statement of ATX, the Net revenue increased by $1.50M (4380%) compared to the previous period. The operating income in 2021 decreased by $-116976 (-5%). The net income as per the annual report was -2.28M which decreased by $-61679 (-3%) compared to previous year.

Income Statement Report (2021/2020)

20212020
Total Revenue1.53M34.23k
Gross Profit1.22M-88.99k
Operating Income-2.34M-2.22M
Income Before Tax-2.28M-2.22M
Net Income-2.28M-2.22M

Balance Sheet - ATX 2021 Annual Report

Read further: ATX Balance Sheet Detailed Analysis

The latest balance sheet from annual result of Amplia Therapeutics Limited showed the company increased the cash on balance sheet by $740293 (67%). The Net tangible assets of ATX on the balance sheet were at 2.4M which is $1.73M (260%) more than previous annual report. The total stockholder equity also increased by $1.73M (20%) compared to previous reporting period.

Balance Sheet Statement Report (2021/2020)

20212020
Cash1.85M1.11M
Total Assets10.88M 9.12M
Long Term Debt--
Total Liabilities539.13k 510.62k
Total Shareholder Equity10.34M8.61M
Net Tangible Assets2.4M667.83k

Cash Flow Statement - ATX 2021 Annual Report

The 2021 annual cash flow statement of Amplia Therapeutics Limited showed that the net income decreased by $-61679 (-3%) compared to previous reporting period. Also the capital expenditure of ATX increased by $0 (0%).

As of 2021, the total cash from investing activities was -5.35k and total cash from financing activities was 3.66M.

Cash Flow Statement Report (2021/2020)

20212020
Net Income-2.28M-2.22M
Capital Expenditures-5.35k-5.35k
Dividends Paid--
Total Cash From From Investing Activities-5.35k-5.35k
Total Cash From From Financing Activities3.66M1.96M

Amplia Therapeutics Limited Annual Report History

Income Statement

Income Statement history of Amplia Therapeutics Limited (ASX:ATX)

31 Mar 202131 Mar 202031 Mar 201931 Mar 2018
Total Revenue1.53M34.23k50.47k580.29k
Cost Of Revenue312.01k123.22k155.48k102.69k
Gross Profit1.22M-88.99k-105k477.6k
Research Development2.21M1.07M678.42k3.22M
Selling General Administrative1.13M858.89k860.83k1.55M
Non Recurring----
Other Operating Expenses----62.55k
Total Operating Expenses3.87M2.26M1.94M4.9M
Operating Income-2.34M-2.22M-1.89M-4.32M
Total Other Income Expense Net59.01k3.72k20.28k26.97k
Ebit-2.34M-2.22M-1.89M-4.32M
Interest Expense----
Income Before Tax-2.28M-2.22M-1.87M-4.3M
Income Tax Expense----
Minority Interest----
Net Income From Continuing Ops-2.28M-2.22M-1.87M-4.3M
Discontinued Operations----
Extraordinary Items----
Effect Of Accounting Charges----
Other Items----
Net Income-2.28M-2.22M-1.87M-4.3M
Net Income Applicable To Common Shares-2.28M-2.22M-1.87M-4.3M

Balance Sheet Statement

Balance Sheet Statement history of Amplia Therapeutics Limited (ASX:ATX)

31 Mar 202131 Mar 202031 Mar 201931 Mar 2018
Cash1.85M1.11M1.24M2.23M
Net Receivables1M34.23k-412.01k
Other Current Assets41.3k10.89k-2.47k
Total Current Assets2.94M1.18M1.25M2.64M
Property Plant Equipment5.47k7971.6k-
Intangible Assets7.94M7.94M7.94M-
Total Assets10.88M9.12M9.19M2.64M
Accounts Payable416.83k474.07k394.13k1.14k
Total Current Liabilities539.13k510.62k526.86k279.42k
Total Liab539.13k510.62k526.86k279.42k
Common Stock136.55M132.9M130.95M123.02M
Retained Earnings-125.21M-122.93M-120.92M-120.3M
Treasury Stock-1.01M-1.37M-1.36M-350.31k
Other Stockholder Equity-1.01M-1.37M-1.36M-350.31k
Total Stockholder Equity10.34M8.61M8.66M2.36M
Net Tangible Assets2.4M667.83k726.54k2.36M
Long Term Debt----

Cash Flow Statement

Cash Flow Statement history of Amplia Therapeutics Limited (ASX:ATX)

31 Mar 202131 Mar 202031 Mar 201931 Mar 2018
Net Income-2.28M-2.22M-1.87M-4.3M
Depreciation6728011.59k20.16k
Change To Netincome354.08k205.58k230k160.29k
Change To Account Receivables-1.02M-58.65k403.58k1.2M
Change To Liabilities28.51k-16.24k247.44k-628.45k
Total Cash From Operating Activities-2.92M-2.09M-987.35k-3.55M
Capital Expenditures-5.35k-5.35k-3.19k-4.42k
Total Cashflows From Investing Activities-5.35k-5.35k-3.19k1.86k
Other Cashflows From Financing Activities-400.26k-191.48k-12.14k-12.91k
Total Cash From Financing Activities3.66M1.96M-12.14k-12.91k
Effect Of Exchange Rate-1.41k-2.75k14.4k25.68k
Change In Cash740.29k-132.79k-988.28k-3.53M
Issuance Of Stock4.06M2.15M2.15M2.15M
Dividends Paid----